A Phase 2, adaptive, randomized, open-label, assessor blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) - NUHS Investigational Medicine Unit

Study Details	A Phase 2, adaptive, randomized, open-label, assessor blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
Protocol Number	CYTB323J12201
Phase	II
Therapeutic Area	Rheumatology
Subject Types	With Medical Condition
Indication	Systemic lupus erythematosus
Principal Investigator	Dr Frank Tay
Investigator Product / Device	Rapcabtagene autoleucel
Sponsor	Novartis (Singapore) Pte Ltd